Comparing Cervical Cancer Screening Strategies in an Incarcerated Population
Journal of Women's Health · 2024
DOI: 10.1089/jwh.2023.0513 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Women's Health, 2024. Verfasst von Anna Caroline Cochrane und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Wake Forest University Health Sciences, Winston-Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Early Detection of Cancer, Uterine Cervical Dysplasia, Prisoners. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
To describe the prevalence of cervical intraepithelial neoplasia (CIN), high-risk human papillomavirus (hrHPV) infection, and cervical cancer in a high-risk, underscreened incarcerated population and to evaluate the performance of current cervical cancer screening options to detect cervical precancer (CIN 2/3) in this population. Study Design: Deidentified data were obtained from all cytological, hrHPV DNA, and histopathological testing of cervical biopsies performed on people incarcerated at the North Carolina Correctional Institute for Women between January 1, 2013, and December 31, 2020. These were linked to corresponding demographic data. The proportions of histopathological diagnoses of CIN2+ and CIN3+ immediately preceded by abnormal cytology testing or hrHPV testing were determined, and prevalence differences and 95% confidence intervals were calculated.
Results
A total of 15,319 individuals incarcerated at the North Carolina Correctional Institute for Women had at least one cytology result during 2013-2020. Of these, 2,829 (18%) had abnormal cervical cytology, and 3,724 (24.3%) had positive hrHPV testing. The detection of CIN2+ was 95.9% by preceding abnormal cervical cytology, 89.9% by preceding positive hrHPV testing (p = 0.03), and 96.5% by preceding positive co-testing. The detection rate of CIN3+ was 96.6% by preceding abnormal cervical cytology, 90.8% by preceding positive hrHPV testing (p = 0.12), and 96.6% by positive co-testing.
Conclusion
In our sample, primary cytology and co-testing detected CIN2+ at higher rates when compared with primary hrHPV testing. This reinforces that incarcerated populations do not fall into average-risk populations for which current cervical cancer screening options are designed, which should be considered when performing screening in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Wake Forest University Health Sciences, Winston-Salem, North Carolina, USA.
- Department of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.
- Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
- University of North Carolina at Chapel Hill Lineberger Cancer Research Center, Chapel Hill, North Carolina, USA.
ORCID-Profile: Anna Caroline Cochrane
Zitieren
APA
Cochrane, A. C., Bullington, B. W., Prokopowicz, C., Rahangdale, L., & Knittel, A. K. (2024). Comparing Cervical Cancer Screening Strategies in an Incarcerated Population. Journal of Women's Health. https://doi.org/10.1089/jwh.2023.0513
Vancouver
Cochrane AC, Bullington BW, Prokopowicz C, Rahangdale L, Knittel AK. Comparing Cervical Cancer Screening Strategies in an Incarcerated Population. Journal of Women's Health. 2024. doi:10.1089/jwh.2023.0513
BibTeX
@article{Cochrane2024,
author = {Cochrane, Anna Caroline and Bullington, Brooke W and Prokopowicz, Caroline and Rahangdale, Lisa and Knittel, Andrea K},
title = {Comparing Cervical Cancer Screening Strategies in an Incarcerated Population},
journal = {Journal of Women's Health},
year = {2024},
doi = {10.1089/jwh.2023.0513}
}
EUVIMED